跳至主要内容
临床试验/NCT00872391
NCT00872391Unknown不适用

Safety and Efficacy of Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Malignant Melanoma of the Uvea

Medical University of Vienna2 个研究点 分布在 1 个国家目标入组 155 人开始时间: 2009年3月最近更新:
适应症

试验速览

阶段
不适用
入组人数
155
试验地点
2
主要终点
local tumor control (tumor dimensions; secondary complications; visual acuity; survival

研究概览

简要总结

The purpose of this study is to assess the safety and efficacy of hypofractionated stereotactic LINAC radiotherapy with 10 fractions at 6 Gy per fraction at the 80% isodose for the planning target volume (PTV) in patients with uveal melanoma. Patients will be followed-up for 10 years after radiotherapy regarding local tumor control, visual acuity, secondary complications and survival.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The initial height of the melanoma is 7 mm or higher.
  • Juxtapapillary and/or juxtamacular melanomas with a height of 3 mm or higher and if the central tumor distance to the optic disc and/or the macula is 3 mm or less.
  • If other forms of conservative treatment of the melanoma are not possible.

排除标准

  • Prior/Concomitant Treatment.
  • Extrascleral tumor extension is present.
  • If the presence of neovascular glaucoma is detected before treatment.
  • If metastasis is detected at baseline.
  • Previous participation in any study of investigational drugs within 3 month preceding day
  • Pregnant women are not allowed to participate in the study.

结局指标

主要结局

local tumor control (tumor dimensions; secondary complications; visual acuity; survival

次要结局

  • histological assessment of the fraction of living cells in eyes requiring secondary enucleation

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验

Hypofractionated Stereotactic Linear Accelerator... | 临床试验